Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 10, 2010 - Issue 7
Submit an article Journal homepage
620
Views
74
CrossRef citations to date
0
Altmetric
Drug Evaluations

Bapineuzumab

Geoffrey A Kerchner Stanford University School of Medicine, Stanford Center for Memory Disorders, 300 Pasteur Drive, Room A343, Stanford, CA 94305 5235, USA
, MD PhD &
Adam L Boxer Memory and Aging Center, University of California, San Francisco, 533 Parnassus Avenue, Suite U426, Campus Box 1207, San Francisco, CA 94143 1207, USA +1 415 476 0668; +1 415 476 0679; [email protected]
, MD PhD
Pages 1121-1130 | Published online: 24 May 2010

Citations (74)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (10)

Daniela Galimberti & Elio Scarpini. (2016) Emerging amyloid disease-modifying drugs for Alzheimer’s disease. Expert Opinion on Emerging Drugs 21:1, pages 5-7.
Read now
Hayk Davtyan, Andrew Bacon, Irina Petrushina, Karen Zagorski, David H Cribbs, Anahit Ghochikyan & Michael G Agadjanyan. (2014) Immunogenicity of DNA- and recombinant protein-based Alzheimer Disease epitope vaccines. Human Vaccines & Immunotherapeutics 10:5, pages 1248-1255.
Read now
Dijana Novakovic, Marco Feligioni, Sergio Scaccianoce, Alessandra Caruso, Sonia Piccinin, Chiara Schepisi, Francesco Errico, Nicola B Mercuri, Ferdinando Nicoletti & Robert Nisticò. (2013) Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease. Drug Design, Development and Therapy 7, pages 1359-1364.
Read now
Gabriel C Léger & Fadi Massoud. (2013) Novel disease-modifying therapeutics for the treatment of Alzheimer’s disease. Expert Review of Clinical Pharmacology 6:4, pages 423-442.
Read now
Bruno P Imbimbo, Simone Ottonello, Vincenza Frisardi, Vincenzo Solfrizzi, Antonio Greco, Davide Seripa, Alberto Pilotto & Francesco Panza. (2012) Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease. Expert Review of Clinical Immunology 8:2, pages 135-149.
Read now
Geoffrey A Kerchner. (2011) Amyloid imaging for Alzheimer's disease. Expert Opinion on Medical Diagnostics 5:6, pages 527-538.
Read now
Cesare Mancuso, Raffaella Siciliano, Eugenio Barone, David Allan Butterfield & Paolo Preziosi. (2011) Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before. Expert Opinion on Investigational Drugs 20:9, pages 1243-1261.
Read now
Francesco Panza, Vincenza Frisardi, Bruno P Imbimbo, Davide Seripa, Vincenzo Solfrizzi & Alberto Pilotto. (2011) Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads. Expert Opinion on Biological Therapy 11:6, pages 679-686.
Read now
Hossein Samadi & David Sultzer. (2011) Solanezumab for Alzheimer's disease. Expert Opinion on Biological Therapy 11:6, pages 787-798.
Read now
Geoffrey A Kerchner, Maria Carmela Tartaglia & Adam L Boxer. (2011) Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia. Expert Review of Neurotherapeutics 11:5, pages 709-717.
Read now

Articles from other publishers (64)

Ying Hao, Mingrui Dong, Yingtong Sun, Xiaohui Duan & Wenquan Niu. (2023) Effectiveness and safety of monoclonal antibodies against amyloid-beta vis-à-vis placebo in mild or moderate Alzheimer's disease. Frontiers in Neurology 14.
Crossref
Prashanth Punyakoti, Tapan Behl, Aayush Sehgal, Shivam Yadav, Monika Sachdeva, Md. Khalid Anwer, Celia Vargas-De-La-Cruz, Thangavel Venkatachalam, Maaz Naqvi, Raman Verma & Hardeep Singh Tuli. (2023) Postulating the possible cellular signalling mechanisms of antibody drug conjugates in Alzheimer's disease. Cellular Signalling 102, pages 110539.
Crossref
Parth Sharma, Ritchu Babbar, Twinkle Sharma, Piyush Madaan, Sandeep Arora & Vishnu Nayak Badavath. (2023) Anti-Amyloid-β Immunotherapy: A Leading Novel Avenue for Alzheimer's Disease. Mini-Reviews in Medicinal Chemistry 23:1, pages 53-66.
Crossref
. (2021) Retraction: Clinical trials in Alzheimer’s disease’: immunotherapy approaches. Journal of Neurochemistry.
Crossref
Milan Stoiljkovic, Tamas L. Horvath & Mihály Hajós. (2021) Therapy for Alzheimer’s disease: Missing targets and functional markers?. Ageing Research Reviews 68, pages 101318.
Crossref
Steven P. Cercy. (2021) Pericytes and the Neurovascular Unit: The Critical Nexus of Alzheimer Disease Pathogenesis?. Exploratory Research and Hypothesis in Medicine 000:000, pages 000-000.
Crossref
Amrita Date, Vandana S. Nikam, Shariq Syed & Sujata P. Sawarkar. 2021. Immunotherapy – A Novel Facet of Modern Therapeutics. Immunotherapy – A Novel Facet of Modern Therapeutics 247 262 .
Szofia Bullain & Rachelle Doody. (2020) What works and what does not work in Alzheimer’s disease? From interventions on risk factors to anti‐amyloid trials. Journal of Neurochemistry 155:2, pages 120-136.
Crossref
Steven S. Plotkin & Neil R. Cashman. (2020) Passive immunotherapies targeting Aβ and tau in Alzheimer's disease. Neurobiology of Disease 144, pages 105010.
Crossref
Alejandro R. Roda, Laia Montoliu-Gaya, Gabriel Serra-Mir & Sandra Villegas. (2020) Both Amyloid-β Peptide and Tau Protein Are Affected by an Anti-Amyloid-β Antibody Fragment in Elderly 3xTg-AD Mice. International Journal of Molecular Sciences 21:18, pages 6630.
Crossref
Irina Petrushina, Armine Hovakimyan, Indira S. Harahap-Carrillo, Hayk Davtyan, Tatevik Antonyan, Gor Chailyan, Konstantin Kazarian, Maxim Antonenko, Amandine Jullienne, Mary M. Hamer, Andre Obenaus, Olga King, Karen Zagorski, Mathew Blurton-Jones, David H. Cribbs, Harry Lander, Anahit Ghochikyan & Michael G. Agadjanyan. (2020) Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials. Neurobiology of Disease 139, pages 104823.
Crossref
Sarah Schemmert, Elena Schartmann, Christian Zafiu, Bettina Kass, Sonja Hartwig, Stefan Lehr, Oliver Bannach, Karl-Josef Langen, Nadim Joni Shah, Janine Kutzsche, Antje Willuweit & Dieter Willbold. (2018) Aβ Oligomer Elimination Restores Cognition in Transgenic Alzheimer’s Mice with Full-blown Pathology. Molecular Neurobiology 56:3, pages 2211-2223.
Crossref
Barbara Mroczko, Magdalena Groblewska, Ala Litman-Zawadzka, Johannes Kornhuber & Piotr Lewczuk. (2017) Amyloid β oligomers (AβOs) in Alzheimer’s disease. Journal of Neural Transmission 125:2, pages 177-191.
Crossref
Vassilis Cutsuridis & Ahmed A. Moustafa. 2017. Computational Models of Brain and Behavior. Computational Models of Brain and Behavior 99 108 .
A.O. Adeniji, P.W. Adams & V.V. Mody. 2017. Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders. Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders 109 143 .
Rizwanul Haque & Aamir Nazir. 2017. Drug Design: Principles and Applications. Drug Design: Principles and Applications 9 29 .
Jing Liu, Bin Yang, Jun Ke, Wenjia Li & Wen-Chen Suen. (2016) Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer’s Disease Immunotherapy. Drugs & Aging 33:10, pages 685-697.
Crossref
L. E. M. Wisse, H. J. Kuijf, A. M. Honingh, H. Wang, J. B. Pluta, S. R. Das, D. A. Wolk, J. J. M. Zwanenburg, P. A. Yushkevich & M. I. Geerlings. (2016) Automated Hippocampal Subfield Segmentation at 7T MRI. American Journal of Neuroradiology 37:6, pages 1050-1057.
Crossref
Anna Bogstedt, Maria Groves, Keith Tan, Rajesh Narwal, Mary McFarlane & Kina Höglund. (2015) Development of Immunoassays for the Quantitative Assessment of Amyloid-β in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies. Journal of Alzheimer's Disease 46:4, pages 1091-1101.
Crossref
Niels Andreasen, Monica Simeoni, Henrik Ostlund, Pia I. Lisjo, Tormod Fladby, Amy E. Loercher, Gerard J. Byrne, Frances Murray, Paul T. Scott-Stevens, Anders Wallin, Yinghua Y. Zhang, Lena H. Bronge, Henrik Zetterberg, Agneta K. Nordberg, Astrid J. Yeo, Shahid A. Khan, Jan Hilpert & Prafull C. Mistry. (2015) First Administration of the Fc-Attenuated Anti-β Amyloid Antibody GSK933776 to Patients with Mild Alzheimer’s Disease: A Randomized, Placebo-Controlled Study. PLOS ONE 10:3, pages e0098153.
Crossref
Kirsten L. Viola & William L. Klein. (2015) Amyloid ? oligomers in Alzheimer?s disease pathogenesis, treatment, and diagnosis. Acta Neuropathologica 129:2, pages 183-206.
Crossref
Roy O. Weller, Cheryl A. Hawkes, Raj N. Kalaria, David J. Werring & Roxana O. Carare. (2015) White Matter Changes in Dementia: Role of Impaired Drainage of Interstitial Fluid. Brain Pathology 25:1, pages 63-78.
Crossref
Erwin De Genst, Anne Messer & Christopher M. Dobson. (2014) Antibodies and protein misfolding: From structural research tools to therapeutic strategies. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1844:11, pages 1907-1919.
Crossref
. 2014. Behavioral Genetics of the Mouse. Behavioral Genetics of the Mouse 391 446 .
Penelope Ward & Mark Bodmer. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies 851 926 .
Haibin Liu, Lirong Wang, Weiwei Su & Xiang-Qun Xie. (2014) Advances in recent patent and clinical trial drug development for Alzheimer’s disease. Pharmaceutical Patent Analyst 3:4, pages 429-447.
Crossref
Cheryl A. Hawkes, Nimeshi Jayakody, David A. Johnston, Ingo Bechmann & Roxana O. Carare. (2014) Failure of Perivascular Drainage of β-amyloid in Cerebral Amyloid Angiopathy. Brain Pathology 24:4, pages 396-403.
Crossref
David A. Drachman. (2014) The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer's disease. Alzheimer's & Dementia 10:3, pages 372-380.
Crossref
Justin Davis & Robin Couch. (2014) Strategizing the Development of Alzheimer’s Therapeutics. Advances in Alzheimer's Disease 03:03, pages 107-127.
Crossref
Dev Singh, Manish Gupta, Rajesh Kesharwani, Mamta Sagar, Seema Dwivedi & Krishna Misra. (2014) Molecular drug targets and therapies for Alzheimer’s disease. Translational Neuroscience 5:3.
Crossref
William F Goure, Grant A Krafft, Jasna Jerecic & Franz Hefti. (2014) Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics. Alzheimer's Research & Therapy 6:4, pages 42.
Crossref
Jan Vijg & Aubrey D.N.J. de Grey. (2014) Innovating Aging: Promises and Pitfalls on the Road to Life Extension. Gerontology 60:4, pages 373-380.
Crossref
Maria Serpente, Rossana Bonsi, Elio Scarpini & Daniela Galimberti. (2014) Innate Immune System and Inflammation in Alzheimer's Disease: From Pathogenesis to Treatment. Neuroimmunomodulation 21:2-3, pages 79-87.
Crossref
Umer Rashid & Farzana L. Ansari. 2014. Drug Design and Discovery in Alzheimer's Disease. Drug Design and Discovery in Alzheimer's Disease 40 141 .
Maria Laura Bolognesi. 2013. Medicinal Chemistry Approaches to Personalized Medicine. Medicinal Chemistry Approaches to Personalized Medicine 211 226 .
Xiu-Qi Bao, Ning Li, Tao Wang, Xiang-Chen Kong, Wen-Jiao Tai, Hua Sun & Dan Zhang. (2013) FLZ Alleviates the Memory Deficits in Transgenic Mouse Model of Alzheimer’s Disease via Decreasing Beta-Amyloid Production and Tau Hyperphosphorylation. PLoS ONE 8:11, pages e78033.
Crossref
Jiaping Gu, Erin E. Congdon & Einar M. Sigurdsson. (2013) Two Novel Tau Antibodies Targeting the 396/404 Region Are Primarily Taken Up by Neurons and Reduce Tau Protein Pathology. Journal of Biological Chemistry 288:46, pages 33081-33095.
Crossref
Cristina d?Abramo, Christopher M. Acker, Heidy T. Jimenez & Peter Davies. (2013) Tau Passive Immunotherapy in Mutant P301L Mice: Antibody Affinity versus Specificity. PLoS ONE 8:4, pages e62402.
Crossref
C J Westmark. (2012) What’s hAPPening at synapses? The role of amyloid β-protein precursor and β-amyloid in neurological disorders. Molecular Psychiatry 18:4, pages 425-434.
Crossref
Alex E. Roher, David H. Cribbs, Ronald C. Kim, Chera L. Maarouf, Charisse M. Whiteside, Tyler A. Kokjohn, Ian D. Daugs, Elizabeth Head, Carolyn Liebsack, Geidy Serrano, Christine Belden, Marwan N. Sabbagh & Thomas G. Beach. (2013) Bapineuzumab Alters A? Composition: Implications for the Amyloid Cascade Hypothesis and Anti-Amyloid Immunotherapy. PLoS ONE 8:3, pages e59735.
Crossref
Nikolai Lorenzen, Erich E. Wanker & Daniel Otzen. 2013. Amyloid Fibrils and Prefibrillar Aggregates. Amyloid Fibrils and Prefibrillar Aggregates 345 372 .
Kevin Mullane & Michael Williams. (2013) Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesis—but what lies beyond?. Biochemical Pharmacology 85:3, pages 289-305.
Crossref
John G. Elvin, Ruairidh G. Couston & Christopher F. van der Walle. (2013) Therapeutic antibodies: Market considerations, disease targets and bioprocessing. International Journal of Pharmaceutics 440:1, pages 83-98.
Crossref
Juan E. Gutierrez, Brian Eichinger & Kejal Kantarci. 2013. Evidence-Based Neuroimaging Diagnosis and Treatment. Evidence-Based Neuroimaging Diagnosis and Treatment 283 298 .
Ingmar Skoog, Amos D. Korczyn & Alla Guekht. (2012) Neuroprotection in vascular dementia: A future path. Journal of the Neurological Sciences 322:1-2, pages 232-236.
Crossref
Tyler A. Kokjohn, Chera L. Maarouf & Alex E. Roher. (2011) Is Alzheimer's disease amyloidosis the result of a repair mechanism gone astray?. Alzheimer's & Dementia 8:6, pages 574-583.
Crossref
Remy Robert & Kim L. Wark. (2012) Engineered antibody approaches for Alzheimer?s disease immunotherapy. Archives of Biochemistry and Biophysics 526:2, pages 132-138.
Crossref
Francesco PanzaVincenza Frisardi, Bruno P Imbimbo, Giancarlo Logroscino, Davide Seripa, Alberto Pilotto & Vincenzo Solfrizzi. (2012) Amyloid-related imaging abnormalities associated with immunotherapy in Alzheimer’s disease patients. Future Neurology 7:4, pages 395-401.
Crossref
Salvatore Salomone, Filippo Caraci, Gian Marco Leggio, Julia Fedotova & Filippo Drago. (2012) New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. British Journal of Clinical Pharmacology 73:4, pages 504-517.
Crossref
Francesco PanzaVincenza Frisardi, Vincenzo Solfrizzi, Bruno P Imbimbo, Giancarlo Logroscino, Andrea Santamato, Antonio Greco, Davide Seripa & Alberto Pilotto. (2012) Immunotherapy for Alzheimer’s disease: from anti-β-amyloid to tau-based immunization strategies. Immunotherapy 4:2, pages 213-238.
Crossref
Suzanne M. de la Monte. (2012) Contributions of Brain Insulin Resistance and Deficiency in Amyloid-Related Neurodegeneration in Alzheimerʼs Disease. Drugs 72:1, pages 49-66.
Crossref
Heather H. Shih. 2012. Development of Antibody-Based Therapeutics. Development of Antibody-Based Therapeutics 9 32 .
Jiaping Gu & Einar M. Sigurdsson. (2011) Immunotherapy for Tauopathies. Journal of Molecular Neuroscience 45:3, pages 690-695.
Crossref
Eun-Soo Sohn & Eun-Hwa Sohn. (2011) A Study on the R&D Trend and Patent Analysis of Treatments for Degenerative Brain Diseases. Journal of the Korea Academia-Industrial cooperation Society 12:10, pages 4411-4417.
Crossref
. (2011) FEATURES. Asia-Pacific Biotech News 15:09, pages 14-34.
Crossref
Pavan K. Krishnamurthy & Einar M. Sigurdsson. (2011) Therapeutic applications of antibodies in non-infectious neurodegenerative diseases. New Biotechnology 28:5, pages 511-517.
Crossref
Kiren Ubhi & Eliezer Masliah. (2011) Recent advances in the development of immunotherapies for tauopathies. Experimental Neurology 230:2, pages 157-161.
Crossref
Alan M. Palmer. (2011) Neuroprotective therapeutics for Alzheimer's disease: progress and prospects. Trends in Pharmacological Sciences 32:3, pages 141-147.
Crossref
Salim Shah & Howard J Federoff. (2011) Therapeutic potential of vaccines for Alzheimer’s disease. Immunotherapy 3:2, pages 287-298.
Crossref
Philip Williams, Analia Sorribas & Melanie-Jayne R. Howes. (2011) Natural products as a source of Alzheimer's drug leads. Nat. Prod. Rep. 28:1, pages 48-77.
Crossref
Manuel Fernández. 2011. Neurofarmacología Contemporánea. Neurofarmacología Contemporánea 273 300 .
Allal Boutajangout, David Quartermain & Einar M. Sigurdsson. (2010) Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model. The Journal of Neuroscience 30:49, pages 16559-16566.
Crossref
Chera L Maarouf, Ian D Daugs, Tyler A Kokjohn, Walter M Kalback, R Lyle Patton, Dean C Luehrs, Eliezer Masliah, James AR Nicoll, Marwan N Sabbagh, Thomas G Beach, Eduardo M Castaño & Alex E Roher. (2010) The biochemical aftermath of anti-amyloid immunotherapy. Molecular Neurodegeneration 5:1.
Crossref
Francesco Panza, Vincenza Frisardi, Bruno P Imbimbo, Grazia D’Onofrio, Giuseppe Pietrarossa, Davide Seripa, Alberto Pilotto & Vincenzo Solfrizzi. (2010) Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease. Immunotherapy 2:6, pages 767-782.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.